Innovative solutions for the serological detection of HPV16 induced cancer


Product Code: LFT-001

CE IVD, For Professional Use Only
4 tests included

  • For the early detection of HPV16 induced cancer
  • High clinical specificity of 99,5% in early cancer stages
  • Easy to use and fast results
Test principle:Competitive immunoassay in form of a rapid test for the qualitative detection of DRH1 antibody equivalents by means of the antibody clone DRH1
Sample material:Capillary blood, venous blood, serum
Sample volume:1 drop blood or 25 µL of serum

Product-related literature

Hilfrich, R.: Hautkrebsvorsorge PLUS − Die Früherkennung  von HPV bedingten Plattenepithelkarzinomen in der dermatologischen Praxis; Akt. Dermatologie 2018; DOI


Prevo-Check® Product Flyer

Further literature

Castellsague X et al: ICO International HPV in Head and Neck Cancer Study Group: HPV Involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients; J Natl Cancer Inst 2016; 108:djv403

Gillison ML et al: Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma; J Clin Oncol 2015; 33:3235-3242

Hartwig S. et al: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review; BMC Cancer 2012, 12:30

Kreimer AR. et al: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.; Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2): 467-75

Ndiaye C. et al:: PV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis; H. Lancet Oncol 2014; 15:1319-1331

Attner P. et al:: Human papillomavirus and survival in patients with base of tongue cancer; Int. J. Cancer 2011; 128: 2892–2897

View further literature in the Scientific Center